Does LUMASIRAN Cause Product dose omission issue? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Product dose omission issue have been filed in association with LUMASIRAN (OXLUMO). This represents 3.2% of all adverse event reports for LUMASIRAN.
9
Reports of Product dose omission issue with LUMASIRAN
3.2%
of all LUMASIRAN reports
0
Deaths
3
Hospitalizations
How Dangerous Is Product dose omission issue From LUMASIRAN?
Of the 9 reports, 3 (33.3%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUMASIRAN. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does LUMASIRAN Cause?
Renal transplant (38)
Nephrolithiasis (22)
Drug ineffective (15)
Hospitalisation (15)
Urine oxalate increased (14)
Acute kidney injury (11)
Liver transplant (11)
Laboratory test abnormal (9)
Death (8)
Dialysis (8)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which LUMASIRAN Alternatives Have Lower Product dose omission issue Risk?
LUMASIRAN vs LUMATEPERONE
LUMASIRAN vs LUMIGAN
LUMASIRAN vs LUPRON DEPOT
LUMASIRAN vs LUPRON DEPOT-PED
LUMASIRAN vs LURASIDONE